Search results

Il Decreto Legge 24 gennaio 2012, n. 1, convertito con legge di conversione 24 marzo 2012, n. 27 e pubblicato in Gazzetta Ufficiale n. 71 del 24 marzo 2012 ("DL Liberalizzazioni"), introduce diverse novità in materia di diritto della concorrenza...

The Law Decree of January 24, 2012, no. 1., converted into law by law of March 24, 2012, no. 27 published in the Gazzetta Ufficiale no. 71 of March 24, 2012 ("Liberalizations Decree"), introduces several changes to competition law and consumer protection...

On 4 April 2012, the Office of Fair Trading (OFT) decided to refer the markets for the supply and acquisition of private healthcare in the UK to the Competition Commission (CC) for an in-depth market investigation.  The CC's terms of reference are...

The UK government announced major reforms of the UK competition regime on 15 March 2012. In the following three videos, partners from Clifford Chance's London Antitrust Practice explain and comment on the changes and their impact on businesses in three key areas.   Reform...

The UK Government has announced its plans for reform of the UK competition regime.  The biggest change will be the merger of the Office of Fair Trading and the Competition Commission to create a new, powerful single competition authority. In addition,...

Mit unserer heutigen Ausgabe des "Newsflash" nehmen wir Bezug auf einen Beschluss des Oberlandesgerichts Düsseldorf vom 11.01.2012, wonach es zulässig sein kann, Rabattvereinbarungen ohne europaweite Ausschreibung zu vergeben. Voraussetzung...

In the first of two articles on the impact on pharmaceutical companies of China's antitrust regime, we focus on the changing shape of merger control review.

In this second of two articles exploring the impact of China's antitrust regime on the pharmaceutical industry, we consider in more detail how the day-to-day operations of pharmaceutical companies are affected by China's competition regime, and highlight...

China's pricing regulator, the National Development and Reform Commission ("NDRC"), recently published an announcement (the "NDRC Announcement") ranking the pharmaceutical sector as the worst offender for pricing violations in 2010...

The attached annual review was presented at the IBC 2012 Advanced EU Competition Law conference in London on 17 April 2012 and provides a detailed analysis of the most significant EU cases relating to anti-competitive agreements, abuses of dominance and merger...